Cell Membrane Biomimetic Nanoparticles with Potential in Treatment of Alzheimer's Disease

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2023 Mar 11

PMID 36903581

Authors

Xinyu Zhong

Yue Na

Shun Yin

Chang Yan

Jinlian Gu

Ning Zhang

Fang Geng

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is to blame for about 60% of dementia cases worldwide. The blood-brain barrier (BBB) prevents many medications for AD from having clinical therapeutic effects that can be used to treat the affected area. Many researchers have turned their attention to cell membrane biomimetic nanoparticles (NPs) to solve this situation. Among them, NPs can extend the half-life of drugs in the body as the "core" of the wrapped drug, and the cell membrane acts as the "shell" of the wrapped NPs to functionalize the NPs, which can further improve the delivery efficiency of nano-drug delivery systems. Researchers are learning that cell membrane biomimetic NPs can circumvent the BBB's restriction, prevent harm to the body's immune system, extend the period that NPs spend in circulation, and have good biocompatibility and cytotoxicity, which increases efficacy of drug release. This review summarized the detailed production process and features of core NPs and further introduced the extraction methods of cell membrane and fusion methods of cell membrane biomimetic NPs. In addition, the targeting peptides for modifying biomimetic NPs to target the BBB to demonstrate the broad prospects of cell membrane biomimetic NPs drug delivery systems were summarized.

Citing Articles

Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications.

Perini H, Matos B, de Oliveira C, da Silva M Beilstein J Nanotechnol. 2024; 15:1619-1626.

PMID: 39717696 PMC: 11665443. DOI: 10.3762/bjnano.15.127.

Biomimetic Nanoparticles for Basic Drug Delivery.

Tikhonov A, Kachanov A, Yudaeva A, Danilik O, Ponomareva N, Karandashov I Pharmaceutics. 2024; 16(10).

PMID: 39458635 PMC: 11510494. DOI: 10.3390/pharmaceutics16101306.

Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures.

Gao C, Xiong R, Zhang Z, Peng H, Gu Y, Xu W Transl Neurodegener. 2024; 13(1):43.

PMID: 39192378 PMC: 11348682. DOI: 10.1186/s40035-024-00436-7.

Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.

Song Q, Li J, Li T, Li H Adv Sci (Weinh). 2024; 11(38):e2403473.

PMID: 39101248 PMC: 11481234. DOI: 10.1002/advs.202403473.

Cell Membrane-Derived Nanovehicles for Targeted Therapy of Ischemic Stroke: From Construction to Application.

Hao C, Sha M, Ye Y, Wang C Pharmaceutics. 2024; 16(1).

PMID: 38276484 PMC: 10819970. DOI: 10.3390/pharmaceutics16010006.

References

Tengjisi , Hui Y, Yang G, Fu C, Liu Y, Zhao C . Biomimetic core-shell silica nanoparticles using a dual-functional peptide. J Colloid Interface Sci. 2020; 581(Pt A):185-194. DOI: 10.1016/j.jcis.2020.07.107. View

McDonald B, Dunbar M . Platelets and Intravascular Immunity: Guardians of the Vascular Space During Bloodstream Infections and Sepsis. Front Immunol. 2019; 10:2400. PMC: 6797619. DOI: 10.3389/fimmu.2019.02400. View

Sun H, Su J, Meng Q, Yin Q, Chen L, Gu W . Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Homotypic Tumors. Adv Mater. 2016; 28(43):9581-9588. DOI: 10.1002/adma.201602173. View

Todd S, Barr S, Roberts M, Passmore A . Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013; 28(11):1109-24. DOI: 10.1002/gps.3946. View

Barua P, Ahn S, Mohamedali A, Liu F . Improved sensitivity in cell surface protein detection by combining chemical labeling with mechanical lysis in a colorectal cancer cell model. Biotechnol Lett. 2020; 42(5):683-695. DOI: 10.1007/s10529-020-02824-1. View

Tulbah A, Lee W . Physicochemical Characteristics and In Vitro Toxicity/Anti-SARS-CoV-2 Activity of Favipiravir Solid Lipid Nanoparticles (SLNs). Pharmaceuticals (Basel). 2021; 14(10). PMC: 8540419. DOI: 10.3390/ph14101059. View

Chen L, Hong W, Ren W, Xu T, Qian Z, He Z . Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct Target Ther. 2021; 6(1):225. PMC: 8182741. DOI: 10.1038/s41392-021-00631-2. View

Melnikova I . Therapies for Alzheimer's disease. Nat Rev Drug Discov. 2007; 6(5):341-2. DOI: 10.1038/nrd2314. View

Marques-Gallego P, de Kroon A . Ligation strategies for targeting liposomal nanocarriers. Biomed Res Int. 2014; 2014:129458. PMC: 4122157. DOI: 10.1155/2014/129458. View

10.

Farshbaf M, Mojarad-Jabali S, Hemmati S, Khosroushahi A, Motasadizadeh H, Zarebkohan A . Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers. J Control Release. 2022; 345:371-384. DOI: 10.1016/j.jconrel.2022.03.019. View

11.

Chai Z, Hu X, Wei X, Zhan C, Lu L, Jiang K . A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. J Control Release. 2017; 264:102-111. DOI: 10.1016/j.jconrel.2017.08.027. View

12.

Pang L, Qin J, Han L, Zhao W, Liang J, Xie Z . Exploiting macrophages as targeted carrier to guide nanoparticles into glioma. Oncotarget. 2016; 7(24):37081-37091. PMC: 5095060. DOI: 10.18632/oncotarget.9464. View

13.

Mahase E . Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns. BMJ. 2021; 375:n3127. DOI: 10.1136/bmj.n3127. View

14.

Zhao H, Song S, Ma J, Yan Z, Xie H, Feng Y . CD47 as a promising therapeutic target in oncology. Front Immunol. 2022; 13:757480. PMC: 9446754. DOI: 10.3389/fimmu.2022.757480. View

15.

Pinheiro R, Granja A, Loureiro J, Pereira M, Pinheiro M, Neves A . RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer's Disease. Pharm Res. 2020; 37(7):139. DOI: 10.1007/s11095-020-02865-1. View

16.

Tsou Y, Zhang X, Zhu H, Syed S, Xu X . Drug Delivery to the Brain across the Blood-Brain Barrier Using Nanomaterials. Small. 2017; 13(43). DOI: 10.1002/smll.201701921. View

17.

Hu C, Fang R, Zhang L . Erythrocyte-inspired delivery systems. Adv Healthc Mater. 2012; 1(5):537-47. DOI: 10.1002/adhm.201200138. View

18.

Martinez J, Molinaro R, Hartman K, Boada C, Sukhovershin R, De Rosa E . Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery. Theranostics. 2018; 8(4):1131-1145. PMC: 5817115. DOI: 10.7150/thno.22078. View

19.

Hou Q, Zhu L, Wang L, Liu X, Xiao F, Xie Y . Screening on-chip fabricated nanoparticles for penetrating the blood-brain barrier. Nanoscale. 2022; 14(8):3234-3241. DOI: 10.1039/d1nr05825h. View

20.

Chowdhury E, Noorani B, Alqahtani F, Bhalerao A, Raut S, Sivandzade F . Understanding the brain uptake and permeability of small molecules through the BBB: A technical overview. J Cereb Blood Flow Metab. 2021; 41(8):1797-1820. PMC: 8327119. DOI: 10.1177/0271678X20985946. View